Prostate cancer within a younger cohort of men, continues to be an increasing problem. With a younger population, greater expectations are present, from erectile function, to continence to oncological outcomes. Significant prostate cancer is increasingly diagnosed in younger men, less than 55 years [1]. In a non-screened population young patients are choosing radical surgery for intermediate and high risk disease [1]. This patient group have high expectations with regards to oncological and functional outcomes. The next question arises, what can we do to improve outcomes?Early-onset prostate cancer (<55 years), differs from prostate cancer diagnosed at an older age in several ways. Firstly, among men with high-grade and advanced-stage prostate cancer, those diagnosed at a young age have a higher cause-specific mortality than men diagnosed at an older age. This highlights biological differences between early and late-onset disease. Early-onset prostate cancer also has a strong genetic component. This indicates that young men with prostate cancer could benefit from evaluation of genetic risk [2]. When the clinico-pathologic features of men 55 years old or less were examined, it was determined this cohort are more likely to have favourable pathologic characteristics [3]. Yet, screening is not standard.The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a statistically significant decrease (29%) in prostate cancer for screened patients, and 23% negative impact on the life-years gained because of quality of life. This was examined further in young patients. As a result Prostate cancer screening can be cost-effective when it is limited to two or three screens between ages 55 to 59 years [4]. American Urological Association (AUA) now no longer recommend testing in men <55 years of age without significant risk factors. The argument for this, is that harms of PSA-testing including overdiagnosis and overtreatment outweigh the benefits [5]. Further supporting this, is the fact that aggressive prostate cancer with prostate cancer mortality occurs frequently in this cohort. Failure to screen these men may lead to delay in diagnosis and loss of opportunity for curative treatment.When examined further, there was no significant difference between the rates of insignificant and high-risk prostate cancer between men <55 years and >55 years, in either the prostate biopsies or prostatectomy specimens [5]. In contrast to this, as part of another cohort, the majority of men <55 years of age had Gleason 8-10 prostate cancer on biopsy with a PSA >4.0 [6]. As these men are at the highest risk for PCSM, failure to screen younger men may result in a missed opportunity for treatment with curative intent. Additionally, this study demonstrated younger men treated with radiotherapy had worse prostate cancer mortality compared to those treated with radical prostatectomy [6]. Although younger patients may have low-risk disease, the extended life expectancy of these patients exposes them to long-ter...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.